18F Fluoroestradiol Radiopharmaceutical with PET/CT

DRUG2 trials

Sponsors

GE Healthcare

Conditions

Metastatic Breast Cancer

Phase 4

Impact of 18F-FES PET on the Therapeutic Treatment of Patients With Metastatic Breast Cancer

Active, not recruitingNCT05486182

GE HealthcareMetastatic Breast Cancer

Start: 2022-02-08End: 2026-01-31Updated: 2025-08-14

Unknown Phase

Clinical Utility of FES F18 PET/CT in Metastatic Breast Cancer Patients

TerminatedNCT05068726

GE HealthcareMetastatic Breast Cancer

Start: 2023-01-05End: 2024-06-01Updated: 2024-07-31

Related Papers

[ <sup>18</sup> F] Fluoroestradiol PET/CT to guide second-line treatment decision-making in patients with estrogen receptor–positive, HER2-negative advanced breast cancer after progression on first-line aromatase inhibitor and CDK4/6 inhibitor: Primary results of ESTROTIMP.

Journal of Clinical Oncology2026-05-27

Clinical utility of [ <sup>18</sup> F]fluoroestradiol (FES) PET/CT to guide second-line treatment decision in patients with ER-positive HER2-negative metastatic breast cancer progressing on first-line endocrine therapy.

Journal of Clinical Oncology2025-05-28

Abstract OT2-01-01: Trial in Progress: Clinical Utility of Fluoroestradiol F18 PET/CT in Metastatic Breast Cancer Patients with ER-Positive and HER2-Negative Primary Lesions after Progression on First Line Hormonal Therapy

Cancer Research2023-03-01